Minerva Neurosciences, Inc: Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates

WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV) a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central

Related Keywords

Helen Shik ,Remy Luthringer ,Frederick Ahlholm ,Minerva Neurosciences ,Janssen Pharmaceutica ,Development Rd Expenses ,Shik Communications ,Drug Administration ,Minerva Neurosciences Inc ,Johnson ,Nasdaq ,New Drug Application ,Label Extension ,Royalty Pharma ,Executive Chairman ,Chief Executive Officer ,Open Label Extension ,Negative Syndrome Scale ,Marder Negative Symptom Factor Score ,Social Performance ,In Process Research ,Private Securities Litigation Reform Act ,Term Liabilities ,Months Ended December ,Aminerva ,Neurosciences ,Reports ,Fourth ,Quarter ,021 ,Financial ,Results ,Business ,Updates ,